



Stuart M. Falber

PARTNER

Co-Chair, Life Sciences Group

BOSTON

+ 1 617 526 6663

STUART.FALBER@WILMERHALE.COM

Stuart Falber exclusively represents clients in the life sciences area. For 30 years, Mr. Falber has served as counsel for a broad range of life sciences clients, ranging from startup private companies to mature public companies, investment banks and venture capital funds.

Mr. Falber's practice focuses on corporate and securities law, with an emphasis on private and public company counseling; representation of issuers, investment banks and investors in venture capital transactions, public offerings and other financing transactions; mergers and acquisitions, including public and private company acquisitions and dispositions, asset acquisitions and sales, and public and private company spinoffs; and corporate collaborations and licensing transactions.

Learn more about Mr. Falber's practice and how he can support your startup on WilmerHaleLaunch.com.

Professional Activities

Mr. Falber is a member of the American Bar Association, the Massachusetts Bar Association and the Boston Bar Association. He previously served as a member of the Boston Bar Association's 2017 Life Sciences Conference Advisory Committee.

Solutions

Capital Markets

Emerging Company and
Venture Capital

Corporate Governance and
Disclosure

Life Sciences

Cross-Border Transactions

Mergers and Acquisitions

Experience

VENTURE CAPITAL TRANSACTIONS

- Seaport Therapeutics in its \$100 million Series A financing round
- Accent Therapeutics, Inc. in its \$40 million Series A financing round
- Apellis Pharmaceuticals, Inc. in its \$60 million Series E financing round
- Decibel Therapeutics in its \$82 million Series D financing round
- Disarm Therapeutics, Inc. in its \$30 million Series A financing round
- Dyne Therapeutics in its \$115 million Series B financing round
- Flare Therapeutics, in its \$123 million Series B financing round
- Generation Bio Co. in its \$100 million Series B financing round
- Trevi Therapeutics, Inc. in its \$50 million Series C financing round
- Atlas Venture, Abingworth Ventures and other funds in venture and strategic financings

PUBLIC OFFERINGS

- The underwriters in its follow-on public offering of Amylyx Pharmaceuticals, Inc. in October 2022
- Aileron Therapeutics, Inc., in its initial public offering and in multiple follow-on offerings including its \$35.9 million follow-on offering in January 2021
- Apellis Pharmaceuticals, Inc. in its \$150 million initial public offering and in multiple follow-on offerings, including its \$404.2 follow-on public offering in January 2020
- Decibel Therapeutics, Inc. in its \$127 million initial public offering
- Generation Bio Co., in its \$230 million initial public offering and its \$225.4 million follow-on offering in January 2021
- Dyne Therapeutics in its \$268 million initial public offering and its \$168 million follow-on offering in January 2021
- Epizyme in multiple follow-on public offerings, including its \$172.5 million public offering in October 2019
- Idera Pharmaceuticals, Inc. in multiple follow-on public offerings, including its \$57.5 million public offering in October 2017
- Tetraphase Pharmaceuticals, Inc. in its \$80.5 million initial public offering and in multiple follow-on public offerings, including its registered direct offerings on October 2019 and January 2020
- Tokai Pharmaceuticals in its \$105.3 million initial public offering
- Trevi Therapeutics, Inc. in its \$70 million initial public offering

MERGER AND ACQUISITION TRANSACTIONS

- Alkermes in its acquisition of Rodin Therapeutics for an upfront cash payment of

\$100 million and up to \$850 million in potential milestone payments

- Braintree Laboratories in its sale to Sebelo Pharmaceuticals
- Decibel Therapeutics, Inc. in its sale to Regeneron Pharmaceuticals, Inc.
- Disarm Therapeutics in its sale to Eli Lilly and Company for an upfront payment of \$135 million plus up to an additional \$1.225 billion in potential milestone payments
- Epizyme in its sale to Ipsen for \$247 million
- Gemini Therapeutics, Inc. in its \$175 million reverse merger transaction with Disc Medicine
- Gloucester Pharmaceuticals, Inc. in its sale to Celgene, Inc. for up to \$640 million, including contingent payments
- Investors Abingworth Bioventures and Atlas Venture in the sale of IFM Therapeutics to Bristol-Myers Squibb
- Tetraphase Pharmaceuticals in its merger with La Jolla Pharmaceuticals
- Tokai Pharmaceuticals Inc. in a share purchase agreement with Otic Pharma Ltd.
- The Medicines Company in its acquisition of Incline Therapeutics for up to \$390 million, including contingent payments
- Penwest Pharmaceuticals Co. in its sale to Endo Pharmaceuticals, Inc. for \$144 million
- Transkaryotic Therapies, Inc. in its sale to Shire Pharmaceuticals Group plc for \$16 billion

PIPE AND 144A TRANSACTIONS

- Apellis Pharmaceuticals in its \$220 million and \$329 million convertible note offerings and in its \$107.5 million convertible note exchange
- The Medicines Company in 144A convertible note offerings, including its \$350 million offering
- Aileron Therapeutics in its \$26 million PIPE transaction
- Argos Therapeutics, Inc. in multiple PIPE transactions, including its \$60 million PIPE transaction
- Spring Bank Pharmaceuticals, Inc. in its \$15 million PIPE transaction
- Idera Pharmaceuticals, Inc. in PIPE transactions raising a total of \$17 million
- New Leaf Ventures in a PIPE transaction by MEI Pharma, Inc. raising a total of \$27.5 million

CORPORATE COLLABORATIONS AND LICENSING TRANSACTIONS

- Epizyme in a collaboration with Royalty Pharma, including equity and royalty sale
- Apellis Pharmaceuticals, Inc. in a risk-sharing collaboration with SFJ Pharmaceuticals
- ZIOPHARM Oncology, Inc., Braintree Laboratories, Inc. and Idera Pharmaceuticals, Inc. in various licensing transactions

Recognition



***Selected as a “Go To Lawyer” in
Massachusetts***

Massachusetts Lawyers Weekly

2021



***Named Among the Best Lawyers in
America for Biotechnology, Life
Sciences and Corporate Law***

Best Lawyers in America

2017–2023



***Shortlisted for Corporate Attorney of
the Year***

LMG Life Sciences

2023

- Recognized by *LMG Life Sciences* as a "Life Sciences Star" in 2018–2023 and shortlisted as the 2019 and 2023 Corporate Attorney of the Year.
- Named one of the 2017–2023 *Best Lawyers in America* in the areas of biotechnology, life sciences and corporate law.
- Named a 2021 "Go To Lawyer" by *Massachusetts Lawyers Weekly* in its inaugural ranking of business lawyers.
- Named to *Boston Magazine's* inaugural Top Lawyers list in 2021, 2022 and 2023 in the area of corporate law.
- Recommended by *The Legal 500 United States* for healthcare: life sciences and capital markets: equity offerings.
- Recognized as a leading lawyer in the 2018 *Life Sciences Expert Guide*.

Credentials

EDUCATION

JD, University of Pennsylvania
Law School

magna cum laude

*Order of the Coif; Senior Editor,
University of Pennsylvania Law
Review*

BA, Tufts University

cum laude

ADMISSIONS

Massachusetts